Comparisons of the proportion of patients prescribed angiotensin‐converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB)/ARNI, beta‐blockers, mineralocorticoid receptor antagonists (MRA) and sodium–glucose co‐transporter 2 inhibitors (SGLT2i) in the four groups in patients with HF, excluding contraindications, based on time since centre accreditation, are shown in Figure 2 and online supplementary Table S7, which are further split by HF type in online supplementary Table S8. This evidence concerns the gene ACE and hydrops fetalis.